Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

OBIO Overall Winner 6-Pillar Tally: VIVS 2 – 3 OBIO (1 Tie) Matrix Metrics: VIVS 2 – 6 OBIO

As of Nov 19, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas OBIO carries 37.8/100 (SELL) at $7.00 (N/M Forward P/E, -195.4% operating margin).

  • Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.8/100 SELL vs. VIVS 36.8/100 SELL) and 1.14β · 86% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both VIVS (36.8/100 SELL) and OBIO (37.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs OBIO
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.00
-6.17% 1D
Market Cap $587.1M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.14β · 86% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 50.0 Fund 36.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 62
RSI-14: 61.8 · SMA20: $6.14 · SMA50: $6.00

6-Pillar Scorecard Institutional Category Breakdown (VIVS 2 – 3 OBIO)

Columns: Metric · VIVS · OBIO
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.6x 19.1x
2. Growth & Scale OBIO
Revenue Growth (YoY) -51.4% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $112,000 $31M
Market Cap $2.4M $587.1M
3. Profitability & Quality OBIO
Gross Margin N/A 99.6%
Operating Margin -10117.0% -195.4%
Net Profit Margin 0.0% -182.5%
Return on Equity (ROE) -343.1% -182.3%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$11M EBITDA -$64M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.4M Net Cash $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile N/A (N/A) 78.2% (21st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (2) vs OBIO (6)
Institutional Metric VIVS OBIO Criterion Row Edge
Market Capitalization
Scale
$2.4M $587.1M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-51.4% -89.4% Higher Growth VIVS
Operating Margin (TTM)
Profitability
-10117.0% -195.4% Higher Margin OBIO
Net Profit Margin
Profitability
0.0% -182.5% Higher Margin VIVS
Return on Equity (ROE)
Capital Efficiency
-343.1% -182.3% Higher ROE OBIO
52-Week Range Position
Momentum
5% ($0–$3) 81% ($3–$8) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 1.14β · 86% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 37.8 / 100 (SELL) Higher Composite OBIO
Trailing 12M Revenue (USD)
Operating Scale
$112,000 $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · 19.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +44.1 pp
VIVS: +64.69% · OBIO: +20.59%
3M Horizon OBIO +28.68 pp
VIVS: +1.92% · OBIO: +30.6%
6M Horizon OBIO +148.98 pp
VIVS: -78.25% · OBIO: +70.73%
1Y Horizon OBIO +152.47 pp
VIVS: -86.99% · OBIO: +65.48%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VIVS Revenue OBIO Revenue VIVS Op. Margin OBIO Op. Margin Margin Leader
FY2018 $0M N/A -766.3% N/A VIVS
FY2019 $0M N/A -882.4% N/A VIVS
FY2020 $0M N/A -977.9% N/A VIVS
FY2022 $0M $0M -765.3% -924.3% VIVS
FY2023 $0M $0M -4792.2% -1866.2% OBIO
FY2024 $0M $0M -13840.4% -2437.5% OBIO
FY2025 $0M $30M -8761.1% -154.7% OBIO
FY2026 $0M N/A -8768.7% N/A VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
35d in phase · OBV ACCUMULATION
Current IV 78.2%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $587.1M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VIVS vs OBIO Key Questions & Quantitative Answers

As of Nov 19, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas OBIO carries 37.8/100 (SELL) at $7.00 (N/M Forward P/E, -195.4% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.8/100 SELL vs. VIVS 36.8/100 SELL) and 1.14β · 86% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both VIVS (36.8/100 SELL) and OBIO (37.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), VIVS cumulative revenue shifted N/A while OBIO shifted N/A. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 19.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.14β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.